Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
about
Tapentadol hydrochloride: A novel analgesicDiabetic neuropathic pain: Physiopathology and treatmentPathways in the diagnosis and management of diabetic polyneuropathyGuidelines in the management of diabetic nerve pain: clinical utility of pregabalin.Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Driving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Combining opioid and adrenergic mechanisms for chronic pain.Treatment of painful diabetic neuropathyBurning through the pain: treatments for diabetic neuropathy.Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.Tapentadol extended release in the management of peripheral diabetic neuropathic painA pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathyA retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.Pharmacological treatment of diabetic peripheral neuropathy.Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain SeverityPatient considerations in the use of tapentadol for moderate to severe pain.Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painPharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature.Current considerations for the treatment of severe chronic pain: the potential for tapentadol.Tapentadol extended-release for treatment of chronic pain: a review.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Tapentadol for pain: a treatment evaluation.Tapentadol extended release: in adults with chronic pain.An update in options for the treatment of pain: a review of new opioid formulations.Tapentadol extended release for chronic pain patients.Cancer pain management: what's new?Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy.New and developing drugs for the treatment of neuropathic pain in diabetes.Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy.Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy.Pharmacokinetic considerations for therapies used to treat interstitial cystitis.Improving acute pain management in emergency medicine.Treatment of painful diabetic peripheral neuropathy.
P2860
Q24629365-D2A24DEA-36FB-405D-8611-25785F2BA58FQ27004604-EF567416-CCD8-4A4B-A2D9-F6ED55CEA829Q28082465-DA0D5B86-7EE3-4D94-83DC-0DF4B5CE3F4BQ30537158-926A5D10-8747-430A-B35D-C03C2EE434ADQ30830216-0AAD5D01-062A-409C-9952-6016E680A15AQ31128284-A09E5635-08D3-4613-AE51-1C92045D8E90Q33583006-EA2B14E9-5DF8-4B68-858B-CDE8CEAECED0Q33938745-4C8D35B5-D899-42DC-B467-7415CD3E06C3Q34434307-2E9A173C-99DC-49AC-861B-4EB1E43B6D25Q34456265-043DD148-01CF-4046-9FF4-E8EC3CEE0600Q34485306-2C1F5616-FC25-4012-812F-D59BB6C3174BQ34628322-7FEF4BAB-583F-45C1-99C4-17A0346643AEQ34756198-6BA90650-FA3C-4E9C-A079-47E979A545F7Q34982228-F4021367-CEB0-4570-BD33-06B8F2E8CADDQ34990241-D57C7B16-9AC1-45EF-AF5A-7FC5B92DE53AQ35576767-D75FF9C6-C157-4A4D-BC8E-2F60BE8DB22AQ35605900-6E039D07-63DA-4278-865F-4D45DA5AAF24Q35669997-7B68D457-BB8B-490A-A951-188E3E2C91FDQ35752535-636B84DF-64CA-436C-8FF5-9805F2B8AB2CQ36293649-0B6B6B26-768B-46FF-932F-07358BB3BBFEQ36684873-5A7A7DA9-8BA2-45D1-9897-899E246EBE26Q36973391-1773C7C6-7262-4785-B776-63810D96E545Q36991981-C77E657E-653D-4EDC-AA55-CFC8BA991886Q37115472-A3E40AF3-A266-4EFD-BB12-98AD533896E0Q37907386-B3027759-9232-496D-9C00-9B7B2A59B80FQ37907389-0CD0F5CE-C067-49DE-BDA9-0D0605592A5FQ37925605-8D7E455D-DEDD-4836-A818-F6E3F466AB7FQ37930962-BD207C08-6EBA-48A6-A1C5-765ABB2A6B39Q37970786-6B447CAE-FB7A-4667-A800-FC79F1641315Q37982435-7E82687F-5D41-4DD8-AE18-D09255BCF4EBQ37992491-EED7D243-202D-4B48-890E-A46E3FCE0529Q38074832-54CA0DA5-5723-406B-96A5-6B3D283A08EDQ38086150-4110373F-1A62-4E53-8E6A-A437ABDB8D71Q38093664-86C28C27-9467-45BC-BA9D-06E09351D682Q38114817-600530E8-1742-4EAD-BC5F-B89E2A7A774EQ38157029-765B3BF6-F7DE-4C6B-9947-2F18AB45314BQ38187698-2A764B03-B144-46D8-9326-9C4588AC5317Q38195318-C4669AA6-4F48-4BDD-9CDE-9F5FFBE45817Q38317178-733ED927-BA26-4D8C-B9D9-CA050A37D540Q38329620-A7BA1DCC-2DF1-490F-8BA8-DF3BFC1C11C9
P2860
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@ast
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@en
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@nl
type
label
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@ast
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@en
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@nl
prefLabel
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@ast
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@en
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@nl
P2093
P1476
Safety and efficacy of tapenta ...... wal, placebo-controlled trial.
@en
P2093
Akiko Okamoto
Douglas Y Shapiro
Juergen Haeussler
Mila Etropolski
Robert Lange
Sherwyn Schwartz
P304
P356
10.1185/03007995.2010.537589
P407
P577
2011-01-01T00:00:00Z